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Alemtuzumab induction in kidney transplant recipients
ABSTRACT
Introduction: Induction therapy has been 
used in sensitized patients, re-transplants, 
and in patients who have high risk to delayed 
graft function (DGF) after renal transplanta-
tion. Methods: Retrospective study with aim 
to compare transplant endpoints between 
recipients of deceased donors which have re-
ceived induction with alemtuzumab (n = 9) 
versus thymoglobulin (n = 18). Patients were 
matched for age, duration of dialysis treat-
ment and cold ischemia time. Results: There 
were no differences at demographic charac-
teristics. All patients received kidney grafts 
from deceased donors and 67% of these 
donors met the expanded criteria. The inci-
dence of DFG was similar in alemtuzumab 
and thymoglobulin groups, 55% and 56%. 
At 12 months, rates of rejection free survival 
(67% versus 89%, p = 0,13), graft surviv-
al (62,5% versus 76,6%; p = 0,73), graft 
with death censored (62,5% versus 76,6%; 
p = 0,82) and patient survival (83,3% ver-
sus 81,2%; p = 0,63) were similar between 
the two groups. Viral infections and renal 
function were similar between groups. At 
the end of the first month, alemtuzumab pa-
tients displayed a fewer lymphocyte number 
(135 ± 78 versus 263 ± 112 N/mm3, p < 
0,05) followed by a more rapid recovery 
after 3 months (day 90: 683 ± 367 versus 
282 ± 72 N/mm3; p < 0,05). Cost associ-
ated with alemtuzumab and thymoglobulin 
inductions therapies were R$ 1,388.00 and 
R$ 7,398.00. Conclusion: In this cohort of 
patients, alemtuzumab induction showed ef-
ficacy and safety comparable to thymoglob-
ulin but with significant cost reduction. 
Keywords: kidney transplantation, immu-
nosuppressive agents, monoclonial anti-
bodies.
[J Bras Nefrol 2010;32(1):89-97]©Elsevier Editora Ltda.
INTRODUCTION
Administration of biological agents that 
cause lymphocyte depletion in peripheral 
blood and lymphoid tissues is one strategy 
of induction, in addition to the use of mo-
noclonal anti-interleukin-2 (IL-2) recep-
tor antibodies. That strategy is indicated 
after renal transplantation to reduce the 
incidence and severity of acute rejection 
episodes, mainly in patients traditionally 
classified as at high immune risk, such as 
highly sensitized patients, retransplanted 
patients, and pediatric or Afro-American 
recipients.1,2,3 This therapeutic strategy 
has also been more frequently used in pa-
tients whose grafts fail to show immediate 
renal function, enabling a delay in starting 
calcineurin inhibitors, and, consequently, 
a faster recovery of renal function.4,5,6 
Finally, those biological agents have allo-
wed the use of immunosuppressive regi-
mens with or without reduced doses of 
corticosteroids or calcineurin inhibitors 
in some subgroups of patients.7,8,9 The 
confirmed efficacy and possible combi-
nation with several immunosuppressive 
regimens are the main reasons for the re-
cent increase in induction use, especially 
in transplant centers in the United States. 
However, the benefits of that strategy are 
somehow minimized by its high cost and 
higher morbidity and mortality observed 
after renal transplantation. Higher inci-
dences of infections (mainly cytomegalo-
virus and polyomavirus) and neoplasias 
(especially lymphoproliferative disease) 
have already been reported in several cli-
nical studies and retrospective analyses of 
data bases.10 
Thymoglobulin (Thymoglobuline®) is 
a immunosuppressive agent composed of 
polyclonal antibodies directed against a 
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When combined with sirolimus (SRL), the incidence 
of acute rejection episodes was 27.6%, and some of 
those episodes had a humoral component, requiring 
specific treatment.20 The use of alemtuzumab and 
maintenance of immunosuppression with calcineu-
rin inhibitors and mycophenolate mofetil (MMF), 
with no corticosteroid, has resulted in reducing the 
incidence of acute rejection to 9.1%.21 This was 
probably due to the fact that memory T cells, more 
resistant to depletion and to the action of corticoste-
roids and SRL, are sensitive to calcineurin inhibitors, 
particularly tacrolimus (TAC).22
This study aimed at assessing the efficacy and sa-
fety of the use of alemtuzumab in an initial series of 
renal transplanted patients.
 
MATERIAL AND METHODS
PATIENTS
This study assessed nine patients who received induc-
tion therapy with alemtuzumab between May 22 and 
August 20, 2007. 
STUDY DESIGN
Alemtuzumab induction therapy was used in the 
following patients: (i) recipients of organs from ex-
panded-criteria deceased donors; (ii) recipients of or-
gans with cold ischemia time longer than 24 hours; 
(iii) sensitized recipients (panel reactive antibodies 
greater than 50%); (iv) patients undergoing second 
transplantation. 
For comparison analysis, 18 patients who had re-
ceived thymoglobulin between November 1, 2005, 
and April 9, 2006, were selected. Their use indications 
met the same criteria described for alemtuzumab. The 
following variables were used for pairing: (i) recipient’s 
age; (ii) dialysis time; (iii) cold ischemia time. The 
analysis was retrospective with data from at least one-
year follow-up for all patients. Efficacy and safety were 
assessed prior to transplantation on days 7, 14, and 30, 
and after transplantation on months 3, 6, and 12.  
DEFINITIONS
Expanded-criteria deceased donor was defined as a do-
nor over the age of 60 years or aged from 50 to 59 years 
with at least two of the following conditions: systemic 
arterial hypertension, creatinine higher than 1.5 mg/dL, 
and cerebro-vascular accident as cause of death.23 
Renal graft loss was defined as the need for 
dialysis for more than 30 consecutive days or a new 
transplantation. Delayed graft function (DGF) was 
defined as the need for dialysis in the first seven days 
large variety of T and B cell antigens, antigens of the 
major histocompatibility complex (MHC), NK cells, 
adhesion molecules, and chemokine receptors.11,12 
The mechanism of action results predominantly 
from the rapid, intense and prolonged depletion of 
T lymphocytes in peripheral blood and lymphoid 
tissues. That pharmacodynamic effect occurs in a 
dose-dependent way through mechanisms involving 
antibody-mediated cytotoxicity, cell-mediated cyto-
toxicity, and apoptosis, limiting tissue migration du-
ring organ reperfusion or acute rejection episodes.13,14 
In some studies, the use of thymoglobulin has been 
associated with a lower incidence and duration of 
delayed graft function4, lower incidence of acute 
rejection, and better graft survival.14 However, thy-
moglobulin has been approved and registered only 
for the treatment of acute rejection. Thus, its dosage 
and length of treatment in induction strategies have 
not been systematically tested, still requiring better 
characterization. Currently, the total of 6 mg/kg is 
often used, in a single dose, usually before transplan-
tation, or fractioned doses between the first and fifth 
postoperative days. 
Alemtuzumab (Campath®) is a humanized mo-
noclonal antibody directed against CD-52 antigen, 
whose biological function is still unknown. The CD-
52 antigen is widely expressed in all lymphocyte li-
neages (except for plasma cells), macrophages, mo-
nocytes, and eosinophils. Alemtuzumab causes rapid 
and deep depletion of T and B cells in peripheral 
blood, but monocytes, macrophages, and memory T 
cells are relatively more resistant to its pharmaco-
dynamic effect.15 Although alemtuzumab has been 
approved only for the treatment of lymphoid neo-
plasias, it has been used, due to its mechanism of 
action, after renal transplantation and autoimmune 
diseases, such as rheumatoid arthritis, vasculites, 
and multiple sclerosis.16,17 Similarly to thymoglo-
bulin, the administration dosage of alemtuzumab is 
varied, and doses of 20 to 30 mg, in single or frac-
tioned infusion, in the perioperative period are the 
most commonly used.
Alemtuzumab was tested in renal transplantation 
for the first time in 1998, and showed a relative effi-
cacy in the prophylaxis of rejection when administe-
red in association with low doses of cyclosporine.18 
In subsequent studies, the isolated use of alemtuzu-
mab caused cortico-sensitive acute rejection episo-
des in all recipients, which resulted in banning its 
use as an immune-tolerance inducing agent.19 Later, 
alemtuzumab was used as induction therapy in as-
sociation with several immunosuppressive regimens. 
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after transplantation. Patients were classified as lost 
to follow-up when definitively transferred to be 
followed up at another center without coming back 
for at least one visit every six months.
Acute rejection episodes were diagnosed based 
on acute graft failure and classified as biopsy-pro-
ven acute rejection (BPAR) in case of histological 
confirmation.
Patients with no dialysis access and clear-
ly identified in the transplant program of the State 
Health Secretariat were prioritized recipients for 
transplantation.
Post-transplantation diabetes mellitus (PTDM) 
was defined as the need for initiating treatment with 
oral hypoglycemic agents or insulin.
IMMUNOSUPPRESSION INDUCTION THERAPY
Alemtuzumab (Campath, Millenium Pharmaceutics®, 
Cambridge, USA, presentation: 30 mg/mL vial) was 
administered at the single dose of 30mg diluted in 
200mL of saline solution, through intravenous infu-
sion for 3 hours on the first postoperative day. 
Thymoglobulin (Thymoglobuline, Genzyme®, 
New Jersey, USA, presentation: 25 mg vial) was admi-
nistered at the dose of 1 mg/kg/day, diluted in 500mL 
of saline solution, through intravenous infusion for 
6 to 8 hours. The daily administration of the drug 
was monitored by use of peripheral lymphocyte count 
as follows: the daily dose of the drug was suspended 
when the count was lower than 100 cells/mm3; the 
daily dose of the drug was reduced when the count 
was between 100 and 150 cells/mm3; the daily dose 
of the drug was maintained, when the count was be-
tween 150 and 250 cells/mm3; and the daily dose of 
the drug was increased, when the count was higher 
than 300 cells/mm3. The duration of treatment with 
thymoglobulin ranged from 1 to 12 days, depending 
on the patient’s daily clinical assessment, mainly re-
garding the renal function recovery signs. 
MAINTENANCE IMMUNOSUPPRESSION
Tacrolimus was administered at the dose of 0.2-0.3 
mg/kg/day divided into two equal daily doses, and 
monitored by use of blood residual concentration. 
Adjuvant therapy was individualized, and fixed do-
ses of mycophenolate sodium (MPS, 1440 mg/day), 
mycophenolate mofetil (MMF, 2000 mg/day), or 
azathioprine (AZA, 1.5-2.0 mg/kg/day) were used. 
Prednisone was administered to all patients at the ini-
tial dose of 0.5 mg/kg/day (maximum of 30 mg/day), 
and progressively reduced to 0.2 mg/kg/day, reaching 
10 mg/day 90 days after transplantation.
PROPHYLAXIS
All patients received prophylactic treatment for pneu-
mocystosis with sulfamethoxazole trimethoprim star-
ting in the postoperative period and continuing until 
six months after renal transplantation. 
Although the patients used anti-lymphocyte an-
tibodies, no prophylaxis against cytomegalovirus 
infection was performed. The cytomegalovirus an-
tigenemia test was monitored weekly, and from the 
time it became positive, patients received preventive 
treatment with gancyclovir. 
EFFICACY AND SAFETY PARAMETERS 
The primary outcomes assessed were as follows: inci-
dence of delayed graft function (DGF) and analysis of 
acute rejection-free graft and patient survivals by the 
end of 12 months after transplantation.
The secondary outcomes included the analysis of 
infectious episodes (number of patients with at least 
one infectious episode, infectious episodes per pa-
tient, hospitalization time, and diagnosis), incidences 
of PTDM and post-transplantation lymphoprolifera-
tive disorders (PTLP). Safety analyses also included 
hematologic assessments, fasting glycemia, and renal 
function evaluation, measured through serum creati-
nine and estimated creatinine clearance through the 
method proposed by Cockroft and Gault.24
COST ANALYSIS OF INDUCTION THERAPY 
The numbers of alemtuzumab and thymoglobulin 
vials used in the immunosuppression protocol of each 
patient were accounted. The analysis was carried out 
with the unitary nominal value of each product (R$ 
1,388.00 per one vial of 30 mg of alemtuzumab and 
R$ 425.45 per one vial of 25 mg of thymoglobulin) 
and the number of vials administered. 
STATISTICAL ANALYSIS
The categorical variables related to the demographic 
characteristics and incidences of DGF and infectious 
episodes, PTDM, and PTLP were compared betwe-
en the two groups using the chi-square test or Fisher 
exact test, depending on the number of observations. 
Continuous noncategorical variables were compa-
red by using independent Student t test. The acute 
rejection-free survival rate, and the graft and patient 
survivals were obtained by using the Kaplan-Meier 
method, and the groups were compared by using the 
log-rank test. The statistical significance level adop-
ted was p < 0.05. The statistical analyses were perfor-
med with the SPSS software, version 7.5 (SPSS Inc., 
Chicago, IL, USA).
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RESULTS
PATIENTS’ PROFILE
The demographic characteristics show that the 
groups were properly paired, because the recipients’ 
age, dialysis time, and cold ischemia time were similar 
(Table 1). 
The population studied was composed exclusively 
of transplant recipients from deceased donors, with a 
mean age of 47 ± 9 years, a long dialysis time (67.9 
± 38.0 months), and high percentage of sensitized re-
cipients. No differences were observed in HLA com-
patibility, degree of sensitization, and number of pre-
vious transplants in the groups studied. In 55% of the 
recipients, the most recent determination of the per-
centage of panel reactive antibodies was over 20%. 
The mean age of donors was elevated (59±9 years), 
and 66% of them were classified as expanded crite-
ria donors. Cold ischemia time exceeded 24 hours in 
67% of the patients. Eleven (40.7%) recipients did 
not receive calcineurin inhibitors in the initial immu-
nosuppressive regimen (Table 1). 
IMMUNOSUPPRESSION
The nine patients received alemtuzumab induction at 
the fixed dose of 30 mg on the first postoperative day. 
The 18 patients of the thymoglobulin group received 
individualized treatment regimens ranging from one 
to 12 days, and with total doses ranging from 75mg 
to 725mg. Compared with the patients who received 
thymoglobulin, those receiving alemtuzumab showed 
initially a greater reduction in lymphocyte count in 
peripheral blood (day 14: 172±129 vs. 390±195 N/
mm3, p<0.05; day 30: 135±78 vs. 263±112 N/mm3, 
p<0.05). However, between the third and 12th month 
after transplantation, a faster recovery was observed 
in that count (day 90: 683±367 vs. 282±72 N/mm3, 
p< 0.05; day 180: 842±500 vs. 439±234 N/mm3, p< 
0.05; day 360: 1269±806 vs. 690±444 N/mm3, p< 
0.05) in patients receiving alemtuzumab (Figure 1).
Tacrolimus doses were lower in the alemtuzumab 
group on days 14, 30, 90, and 180, but the concen-
trations of that drug were similar in both groups. No 
difference was observed between groups regarding 
the mycophenolate doses. The prednisone doses were 
also lower in the alemtuzumab group on days 14, 30, 
and 90 (Table 2). 
EFFICACY ANALYSIS
The incidences of DGF were similar in the alemtu-
zumab and thymoglobulin groups (55% vs. 56%). 
Although BPAR-free survival was 17.6% greater in 
the group receiving thymoglobulin, that difference 
did not reach statistical significance. All BPAR episo-
des were treated with methylprednisolone. Graft sur-
vival (62.5% vs. 66.7%), patient survival (83.3% vs. 
81.2%), and death-censored graft survival (62.5% vs. 
76.6%) were also similar. One death caused by infec-
tion was observed in each treatment group (Table 3). 
SAFETY ANALYSIS
The proportion of patients with at least one infec-
tious episode was higher, but not statistically signifi-
cant, in patients receiving alemtuzumab as compared 
with those receiving thymoglobulin (89% vs. 56%, 
p=0.193). The number of episodes of bacterial pul-
monary infection was statistically greater in the ale-
mtuzumab group (p=0.029), while the incidence of 
other infections, including the viral ones (CMV and 
herpes), was similar in both groups. 
The incidence of PTDM was similar in the groups, 
although fasting glycemia on month 12 was higher in 
the thymoglobulin group (76.0 ± 5.2 mg/dL vs 99.5 ± 
12.2 mg/dL, p<0.05). No PTLP was observed in the 
patients studied. The mean creatinine levels (1.5 ± 0.6 
mg/dL vs. 2.1 ± 1.4 mg/dL) and creatinine clearance 
(61.6 ± 18.2 mL/min and 52.7 ± 26.1 mL/min) were 
similar in both groups at the end of the first post-
transplant year. The thymoglobulin group recipients 
showed lower hemoglobin concentrations on days 7 
(10.3±2.0 vs. 8.5±1.6 mg/dL; p< 0.05) and 14 (10.2 ± 
2.5 vs. 9.0 ± 1.2 mg/dL; p< 0.05) after transplantation 
(Table 4). 
COST ANALYSIS
The cost of the treatment with alemtuzumab was R$ 
1,388.00 per patient. The mean cost of treatment 
Figure 1. Lymphocyte count in peripheral blood during 
the 12 months following renal transplantation in the 
alemtuzumab and thymoglobulin groups (* p < 0.05).
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with thymoglobulin was R$ 7,398.00, ranging from 
R$ 1,276.35 to R$ 12,338.05, depending on the num-
ber of doses received per each patient. 
 
DISCUSSION    
This study population characterizes well the current 
scenario of renal transplantation. The growing dispro-
portion between the number of donors and recipients 
determines the increase in waiting time for transplan-
tation (dialysis time) and in sensitized patients wai-
ting for transplantation, resulting in an increasing 
number of transplantations from expanded-criteria 
donors. There is no definition about the ideal immu-
nosuppressive regimen for such clinical situations, 
which partially accounts for the diversity of immuno-
suppressive strategies already tested. In addition, the 
major outcomes of renal transplantation are signifi-
cantly lower in that population. 
The incidence of DGF was high probably due to the 
characteristics of the transplantations performed, and 
was not influenced by the induction therapy used.25 The 
overall incidence of BPAR (18.5%) was relatively grea-
ter when compared with the incidence of rejection obser-
ved in patients with no DGF, usually ranging from 10% 
to 12%.26 Patients undergoing alemtuzumab induction 
showed a higher incidence of acute rejection (33.3% vs. 
11.1%) and graft loss (33.3% vs. 22.2%) as compared 
with those receiving thymoglobulin, probably due to 
shorter duration of its pharmacodynamic effect, here 
analyzed through the reduction in lymphocyte count in 
peripheral blood. All acute rejection episodes occurred 
after the second month of transplantation, coinciding 
TABELA 1 DEMOGRAPHIC CHARACTERISTICS
                              Grupo Alemtuzumab Thymoglobulin p value
n 9 18 -
Sex (male/female) 6/3 11/7 1.000
Age (years) 45.4 ± 7.8 47.9 ± 9.7 0.510
Ethnicity (white/mixed/black) 7/2/0 9/6/3 0.321
Body mass index - BMI (kg/m2) 23.5 ± 5.0 25.1 ± 3.2 0.322
Type of dialysis (hemodialysis/peritoneal) 8/1 17/1 1.000
Dialysis time (months) 70.7 ± 31.7 65.1 ± 41.5 0.725
 [18 - 120] [17 - 180] 
HLA incompatibilities  2.1 ± 0.9 3.1 ± 1.6 0.107
 [1 - 4] [0 - 6] 
Panel reactive antibodies (%) 14.2 22.5  0.541
 [0 - 89] [0 - 86)] 
 ≥ 20 % 2 (22.2) 6 (33.3) 0.551
 ≥ 50 % 1 (11.1) 5 (27.3) 0.362
Retransplantation 2 (22.2) 2 (11.1) 0.582
Prioritized recipient 2 (22.2) 5 (28.0) 1.000
Donor’s age (years) 61.8 ± 7.6 57.7 ± 9.8 0.282
Donor’s sex (male/female) 6/3 9/9 0.683
Standard-criteria deceased donor 04 (44.4) 04 (22.2) 0.375
Extended-criteria deceased donor 05 (55.6) 14 (77.8) 
Cold ischemia time (hours) 26.1 ± 5.9 25.3 ± 4.6 0.710
 [17 - 35] [20 - 37] 
 ≥ 24 hours 6 (66.7) 11 (61.1) 0.778
 ≥ 30 hours 3 (33.3) 2 (11.1) 0.161
Initial immunosuppression
   Tacrolimus/mycophenolate/prednisone 04 (44.4) 12 (66.7) 0.471
   Mycophenolate/prednisone 05 (55.6) 04 (22.2)
   Azathioprine/prednisone - 02 (11.1)
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Table 3 EFFICACY PARAMETERS 12 MONTHS AFTER RENAL TRANSPLANTATION
Group  Alemtuzumab Thymoglobulin p value
  (n = 9) (n = 18) 
Delayed graft function 5 (55 %) 10 (56 %) 1.00
BPAR-free survival 67.0 % 84.6 % 0.26
Severity (BANFF)      
 IA 1 0
 IB 1 0 
 IIA 1 1   
 IIB 0 0  
 III 0 1
Graft survival 62.5 % 66.7 % 0.82
 Cause of graft loss      
 “de novo” glomerulonephritis 1 0  
 Suspension of immunosuppression 2 1  
 Vascular thrombosis 0 2  
 Primary dysfunction 0 1  
Patient’s survival 83.3 % 81.2 % 0.63
 Cause of death      
 IInfection 1 1  
 Subarachnoid hemorrhage 0 1  
 Pulmonary thromboembolism 0 1     
Death-censored graft survival 62.5 % 76.6 % 0.73
Loss to follow-up 1 (11%) 0 (0%) -
BPAR: biopsy-proven acute rejection
Alemtuzumab induction in renal transplant recipients
with the phase of return to normal lymphocyte count 
in peripheral blood. This has already been reported in 
a retrospective study with 14,362 recipients, whose 
acute rejection incidence at the end of the first year of 
transplantation was greater in the group of patients re-
ceiving alemtuzumab induction as compared with that 
receiving thymoglobulin (19.2% vs. 10.2%; p< 0.001).27 
Prospective studies have also compared the use of in-
duction therapies with thymoglobulin or alemtuzumab 
in renal transplant recipients receiving TAC, TAC and 
MMF, or SRL. 20,21,28 Acute rejection incidences were 
18%, 23%, and 28%, respectively. 
Tabela 2 DOSES AND BLOOD CONCENTRATIONS OF IMMUNOSUPPRESSIVE DRUGS DURING THE 12 MONTHS FOLLOWING RENAL   
 TRANSPLANTATION.
Days      Tacrolimus dose                   Tacrolimus                  Mycophenolate dose                 Prednisone dose  
                   (mg/day)                             (ng/mL)                                (mg/day)                                  (mg/day)
                Alemtuzumab    Thymoglobulin      Alemtuzumab    Thymoglobulin      Alemtuzumab             Thymoglobulin           Alemtuzumab       Thymoglobulin
7 11.5 ± 4.4 14.7 ± 1.8 11.5 ± 3.1 14.2 ± 8.2 1,840.0 ± 379.5 1,440.0 ± 0.0 30.0 ± 0.0 30.0 ± 0.0
14 9.5 ± 1.0 16.3 ± 3.5 * 10.2 ± 2.2 13.3 ± 5.4 1,360.0 ± 240.0 1,329.0 ± 270.4 22.8 ± 5.7 30.0 ± 0.0 *
30 6.0 ± 1.6 14.3 ± 4.6 * 9.0 ± 1.0 11.0 ± 5.0 1,120.0 ± 379.5 1,290.0 ± 276.5 13.9 ± 7.3 25.3 ± 4.8 *
90 4.4 ± 3.3 9.8 ± 4.7 * 5.9 ± 2.6 9.1 ± 3.8 855.0 ± 267.8 1,160.0 ± 300.0 9.7 ± 7.9 15.8 ± 4.2 *
180 3.2 ± 1.1 8.3 ± 4.5 * 6.7 ± 3.8 6.9 ± 2.1 990.0 ± 372.6 1,188.0 ± 296.4 9.2 ± 4.7 11.9 ± 4.1
360 3.3 ± 1.2 7.0  ± 4.3 6.1 ± 3.8 6.5 ± 1.8 1,080.0 ± 415.7 945.0 ± 329.8 7.0 ± 2.7 8.8± 1.7 
* p < 0.05 Alemtuzumab vs. Thymoglobulin.
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Despite the high proportion of organs from exten-
ded-criteria donors and acute rejection incidence, pa-
tients receiving alemtuzumab achieved renal function 
on average 8.9 mL/min higher than that observed in 
patients receiving thymoglobulin (61.6 vs. 52.7 mL/
min). When attributing the value of 10 mL/min for pa-
tients who lost their grafts and carrying the last renal 
function value to those who died before completing 
the first year of transplantation, the results were also 
similar (44.0±28.6 vs. 40.0±28.6 mL/min, p=0.735). 
The occurrence of PTDM was similar in both groups 
(22%) and comparable to that of protocols with no 
induction therapy. Mean glycemia was more elevated 
in patients receiving thymoglobulin. Considering all 
factors involved in that observation, the greatest do-
ses and concentrations of TAC and the greatest doses 
of prednisone used in patients receiving thymoglobu-
lin can have been determinant.
Our study also suggests that patients receiving 
alemtuzumab have a greater incidence of infection as 
compared with those receiving thymoglobulin (89% 
vs. 56%).28,13 Bacterial pneumonia was more frequent 
in the alemtuzumab group (33% vs 0%, p<0.029), 
as also reported in the study by Vathsala et als. 28 
Cytomegalovirus infection was equally present in bo-
th groups (22% vs. 39%, p= ns), but with a higher 
incidence than that reported in another series (6.5% 
vs. 3.3%)29, possibly due to the non systematic use of 
prophylaxis at our center. The prophylactic treatment 
has been associated with reduced incidences of CMV 
infection in other series using induction therapy with 
alemtuzumab (5%)28 or thymoglobulin (10.4%).13 No 
lymphoproliferative disease occurred during follow-
up. 
The cost was an evident difference between the 
induction therapy regimens, as reported by other au-
thors.30 Although expenditures with new hospitali-
zations, other drugs, and treatment of complications 
have not been considered, the cost of using thymoglo-
bulin was, on average, five times greater than that of 
using alemtuzumab (R$ 1,388.00 vs. R$ 7,398.10). 
Due to the intrinsic limitations of the study (retros-
pective nature and reduced sample size), no conclusive 
and sound information could be extracted from that 
analysis. The lack of statistical significance in compa-
ring the outcomes selected could have resulted from 
the reduced sample size (beta error). However, alemtu-
zumab or thymoglobulin induction in the population 
Table 4 SAFETY PARAMETERS 12 MONTHS AFTER RENAL TRANSPLANTATION.
Parameter Alemtuzumab Thymoglobulin p Value
   (n = 9) (n = 18)       
Infection 8 (89%) 10 (56%) 0.193
 Urinary tract 3 (33%) 3 (17%) 0.628
 Cytomegalovirus 2 (22%) 7 (39%) 0.667
 Pneumonia 3 (33%) 0 0.029
 Herpes simplex or zoster 2 (22%) 2 (11%) 0.582
 Tuberculosis 1 (11%) 0 0.333
Post-transplantation diabetes mellitus 2 (22%) 4 (22%) 1.000
Glycemia (mg/dL) 76.0 ± 5.2 99.5 ± 12.2 0.009
Renal function      
 Creatinine (mg/dL) 1.54 ± 0.60 2.17 ± 1.41 0.358
 Creatinine clearance (mL/min) 61.6 ± 18.2 52.7 ± 26.1 0.503
Hematology      
 Hemoglobin (mg/dL) 13.9 ± 1.9 13.5 ± 2.0 0.680
 Hematocrit (%) 41.3 ± 6.2 41.7 ± 5.3 0.896
 White blood cells (N/mm3) 6920 ± 2224 6733 ± 1848 0.860
 Platelets (103 N/mm3) 217.6 ± 40.6 172.7 ± 42.4 0.062
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studied has determined apparently unsatisfactory efficacy 
and safety. Theoretically, a higher dose of alemtuzumab 
(40 mg in a single dose or two doses of 20 mg) could 
increase efficacy in preventing acute rejection. However, 
the diversity of immunosuppressive regimens using ale-
mtuzumab as induction therapy in several centers and the 
possibility of jeopardizing the safety of treatment made 
more sound conclusions impossible. In addition to the hi-
gh incidence of acute rejection, three grafts were lost after 
immunosuppression suspension during severe infectious 
episodes, and two recipients died due to infection. 
Immunosuppressive regimens with or without in-
duction therapy with monoclonal antibodies directed 
to interleukin-2 receptor produce results considered 
to be adequate in most renal transplant recipients. 
However, the ideal immunosuppressive regimen for 
sensitized recipients and recipients from organs of ex-
tended-criteria donors, who represent an increasing 
part of the transplantations annually performed, has 
not yet been identified. Induction therapy, using anti-
body preparations that cause lymphocyte depletion, is 
believed to be necessary in such clinical situations. In 
this exploratory study, alemtuzumab, despite its signi-
ficantly reduced cost, apparently did not show efficacy 
and safety comparable to those of thymoglobulin. 
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